NCT07144163View on ClinicalTrials.gov

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2027

Conditions
Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Interventions
DRUG

Atumelnant

Atumelnant, tablets, once daily by mouth

DRUG

Placebo

Placebo, tablets, once daily by mouth

Trial Locations (5)

3050

Crinetics Study Site, Parkville

4029

Crinetics Study Site, Herston

4102

Crinetics Study Site, Woolloongabba

5000

Crinetics Study Site, Adelaide

6009

Crinetics Study Site, Nedlands

Sponsors
All Listed Sponsors
lead

Crinetics Pharmaceuticals Inc.

INDUSTRY

NCT07144163 - A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter